title: Antibodies for biodefense.
abstract: Potential bioweapons are biological agents (bacteria, viruses, and toxins) at risk of intentional dissemination. Biodefense, defined as development of therapeutics and vaccines against these agents, has seen an increase, particularly in the US following the 2001 anthrax attack. This review focuses on recombinant antibodies and polyclonal antibodies for biodefense that have been accepted for clinical use. These antibodies aim to protect against primary potential bioweapons, or category A agents as defined by the Centers for Disease Control and Prevention (Bacillus anthracis, Yersinia pestis, Francisella tularensis, botulinum neurotoxins, smallpox virus, and certain others causing viral hemorrhagic fevers) and certain category B agents. Potential for prophylactic use is presented, as well as frequent use of oligoclonal antibodies or synergistic effect with other molecules. Capacities and limitations of antibodies for use in biodefense are discussed, and are generally applicable to the field of infectious diseases.
authors: U.S. Army Medical Research and Material Command, Fort Detrick, MD, USA.
authors: Jeffrey W
authors: JW
authors: Froude
authors: Bradley
authors: B
authors: Stiles
authors: Thibaut
authors: T
authors: Pelat
authors: Philippe
authors: P
authors: Thullier
mesh_terms: D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000382:microbiology / Q000628:therapy*; D054045:Biological Warfare Agents / Q000145:classification; D023482:Bioterrorism / Q000517:prevention & control*; D002487:Centers for Disease Control and Prevention, U.S.; D006801:Humans; D051379:Mice; D011817:Rabbits; D011994:Recombinant Proteins / Q000627:therapeutic use*; D014481:United States; D014777:Virus Diseases / Q000628:therapy* / Q000821:virology
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D054045:Biological Warfare Agents; D011994:Recombinant Proteins